NKTX logo

Nkarta Inc. (NKTX)

$1.25

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NKTX

Market cap

$89630505

EPS

-1.74

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.24992

Price on NKTX

Previous close

$1.21

Today's open

$1.22

Day's range

$1.15 - $1.28

52 week range

$1.11 - $3.72

Profile about NKTX

CEO

Paul Hastings

Employees

106

Headquarters

South San Francisco, CA

Exchange

Nasdaq Global Select

Shares outstanding

71704404

Issue type

Common Stock

NKTX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on NKTX

Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026

No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or graft-versus-host disease (GvHD) across 40 patients treated across five indications in the Ntrust program. No deaths and no treatment discontinuations due to adverse events.

news source

GlobeNewsWire • Nov 11, 2026

news preview

Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis Transcript

Nkarta, Inc. ( NKTX ) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis November 9, 2026 8:00 AM EST Company Participants Paul Hastings - CEO & Director Shawn Rose - Chief Medical Officer and Head of Research & Development Nadir Mahmood - President and Principal Accounting & Financial Officer Conference Call Participants Gil Blum - Needham & Company, LLC, Research Division Guillermo Valenzuela Salim Syed - Mizuho Securities USA LLC, Research Division Philip Nadeau - TD Cowen, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, everyone.

news source

Seeking Alpha • Nov 9, 2026

news preview

Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence

In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in the Ntrust-2 study of NKX019, an investigational, allogeneic CAR NK cell therapy. In systemic sclerosis, 6/7 (86%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved a revised Composite Response Index in Systemic Sclerosis (rCRISS)-25 response or greater, with 5/7 (71%) patients achieving an rCRISS-50 response or greater.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. ET, to review initial clinical data from its Ntrust program evaluating NKX019 in myositis and systemic sclerosis being presented at the American College of Rheumatology (ACR) Convergence 2026 in Orlando.

news source

GlobeNewsWire • Nov 6, 2026

news preview

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance

Nkarta NASDAQ: NKTX said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety.

news source

MarketBeat • Sep 27, 2026

news preview

Nkarta to Participate in September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: September 16, 2026 H.C.

news source

GlobeNewsWire • Sep 10, 2026

news preview

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its selection for three scientific presentations at ACR Convergence 2026 being held November 6-11 in Orlando.

news source

GlobeNewsWire • Sep 8, 2026

news preview

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, today announced the appointment of Alyssa Levin to its Board of Directors, where she will also serve as Chair of the Audit Committee. The company has also strengthened its leadership team with two key additions. Clara Cambon-Thiebaud joins as Vice President, Regulatory Affairs, based in New York, and Céline Breda as Vice President, Chemistry Manufacturing and Controls (CMC). This leadership team expansion comes as Cyllene Tx advances its lead candidate, EG110A, towards late-stage clinical development for neurogenic bladder-related incontinence.

news source

GlobeNewsWire • Jul 23, 2026

news preview

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference.

news source

GlobeNewsWire • Jun 26, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Nkarta Inc.

Open an M1 investment account to buy and sell Nkarta Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NKTX on M1